Literature DB >> 24262289

Systemic amyloidoses: what an internist should know.

Giovanni Palladini1, Giampaolo Merlini.   

Abstract

Systemic amyloidoses are rare, complex diseases caused by misfolding of autologous proteins. Although these diseases are fatal, effective treatments exist that can alter their natural history, provided that they are started before irreversible organ damage has occurred. The cornerstones of the management of systemic amyloidoses are early diagnosis, accurate typing, appropriate risk-adapted therapy, tight follow-up, and effective supportive treatment. Internists play a key role in suspecting the disease, thus allowing early diagnosis, starting the diagnostic workup and selecting patients that should be referred to specialized centers, judiciously titrating supportive measures, and following patients throughout the course of the disease. Here we review the pathogenesis, diagnosis and treatment of the most common forms of systemic amyloidoses.
© 2013.

Entities:  

Keywords:  Amyloidosis; Diagnosis; Treatment

Mesh:

Year:  2013        PMID: 24262289     DOI: 10.1016/j.ejim.2013.10.007

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  8 in total

1.  Prevalence, Severity, and Prognostic Value of Sleep Apnea Syndromes in Cardiac Amyloidosis.

Authors:  Diane Bodez; Aziz Guellich; Mounira Kharoubi; Ala Covali-Noroc; Claire-Marie Tissot; Soulef Guendouz; Luc Hittinger; Jean-Luc Dubois-Randé; Jean-Pascal Lefaucheur; Violaine Planté-Bordeneuve; Serge Adnot; Laurent Boyer; Thibaud Damy
Journal:  Sleep       Date:  2016-07-01       Impact factor: 5.849

Review 2.  Novel Therapies in Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Kidney Int Rep       Date:  2017-11-28

3.  Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups.

Authors:  David Rintell; Dena Heath; Florencia Braga Mendendez; Elizabeth Cross; Theodore Cross; Vincent Knobel; Bruno Gagnon; Cameron Turtle; Alan Cohen; Edward Kalmykov; Jonathan Fox
Journal:  Orphanet J Rare Dis       Date:  2021-02-08       Impact factor: 4.123

Review 4.  A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications.

Authors:  Douglas B Kell; Gert Jacobus Laubscher; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-02-17       Impact factor: 3.857

Review 5.  ATTR Epidemiology, Genetics, and Prognostic Factors.

Authors:  Chukwuemeka A Obi; William C Mostertz; Jan M Griffin; Daniel P Judge
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-03-14

6.  Minimally invasive minor salivary gland biopsy for the diagnosis of amyloidosis in a rheumatology clinic.

Authors:  Ridvan Mercan; Berivan Bıtık; Mehmet Engin Tezcan; Arif Kaya; Abdurrahman Tufan; Mehmet Akif Ozturk; Seminur Haznedaroglu; Berna Goker
Journal:  ISRN Rheumatol       Date:  2014-02-23

7.  Three cases of systemic amyloidosis successfully diagnosed by subcutaneous fat tissue biopsy of the hip.

Authors:  Masahisa Arahata; Shigeru Shimadoi; Satosi Yamatani; Shin-Ichi Hayashi; Shigeharu Miwa; Hidesaku Asakura; Shinji Nakao
Journal:  Clin Interv Aging       Date:  2016-08-05       Impact factor: 4.458

Review 8.  Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery.

Authors:  Aldostefano Porcari; Marco Merlo; Claudio Rapezzi; Gianfranco Sinagra
Journal:  Eur J Intern Med       Date:  2020-10-05       Impact factor: 7.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.